One patient with RET mutation has an active metastatic disease (MTC and pheochromocytoma), being under treatment with tyrosine kinase inhibitors; other two patients with RET mutation developed recurrent MTC but no recurrence of PHEO. This evidence concerns the gene RET and medullary thyroid gland carcinoma.